title: The GOAL study: designed to favor a long-acting beta2-agonist?
authors.forename: Graeme P
authors.initials: GP
authors.lastname: Currie
authors.forename: Daniel K C
authors.initials: DK
authors.lastname: Lee
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D016535:Bronchial Hyperreactivity; D004359:Drug Therapy, Combination; D000068298:Fluticasone; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D012107:Research Design; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome
chemical_list: D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol